Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-03-21
2006-03-21
Huff, Sheela J. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007100, C436S540000, C436S536000, C436S538000, C436S518000, C436S529000, C436S525000
Reexamination Certificate
active
07015005
ABSTRACT:
The present invention relates to novel methods and devices for detecting non-complexed prostate specific antigen (PSA), which can be used either alone or in conjunction with total PSA tests to identify patients having either benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy or prostatic adenocarcinoma (CAP). In a biological sample, one can find not only non-complexed PSA, but also PSA which has formed a complex with α1-antichymotrypsin (ACT). The present invention removes or precipitates complexed PSA (PSA-ACT) and ACT from a fluid sample, thereby removing any possible interference due to the binding of complexed PSA to assay reagents. The method requires contacting a biological fluid sample possibly containing a mixture of complexed PSA and non-complexed PSA either with an immuno-precipitating reagent or a device having attached an ACT specific binding partner which in both cases specifically binds only to ACT and the ACT portion of complexed PSA, thereby precipitating ACT and the bound complexed PSA and, thus, leaving any non-complexed PSA unbound and in solution. Then, the sample is measured for non-complexed PSA by means of a conventional specific binding reaction. The device can be a filter having a modified filter media that binds ACT and complexed PSA, while permitting the sample to flow or be pulled through the filter media and into assay reagents. Alternatively, the device can be a removable media that is placed into a sample, allowed to remain long enough to bind any ACT and complexed PSA present, and then withdrawn from the sample prior to running a PSA specific binding assay.
REFERENCES:
patent: 5403745 (1995-04-01), Ollington et al.
patent: 5710007 (1998-01-01), Luderer et al.
patent: WO 92/01936 (1992-02-01), None
patent: WO 95/18381 (1995-07-01), None
Luderer et al. “Measurement of the Proportion of Free to Total Prostate-Specific Antigen Improves Diagnositc Performance of Prostate-Specific Antigen in the Diagnostic Gray Zone of Total Prostate-Specific Antigen” Urology 46:187-194 (1995).
Oesterling. “Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate” Journal of Urology 145:907-923 (1991).
Oesterling et al, “Influence of Patient Age on the Serum PSA Concentration An Important Clinical Observation” Urologic Clinics Of North America 20(4):671-680 (1993).
Alland et al. “Novel Immuonassay for the Meausrement of Complexed Prostate-Specific Antigen in Serum” Clinical Chemistry 44(6):1216-1223 (1998).
Chichibu et al., Journal of Urology (1996) 155(5):1.
Heeb et al., Biochemistry and Molecular Biology International (1995) 37(5):917-923.
Supplementary European Search Report for EP 98 94 4518, mailed on Sep. 28, 2004, 4 pages.
Wang et al., Clinical Chemistry (1997) 43(Suppl.6):S225.
Wu et al., Journal of Clinical Laboratory Analysis (1995) 9(1):15-24.
Wu et al., Journal of Clinical Laboratory Analysis (1995) 9(1):25-31.
Huff Sheela J.
Morrison & Foerster / LLP
Scantibodies Laboratory, Inc.
LandOfFree
Methods and devices for detecting non-complexed prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and devices for detecting non-complexed prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for detecting non-complexed prostate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3597417